Genentech (DNA) and partner Roche said Tuesday that a second late-stage trial for blockbuster drug Avastin in combination with chemotherapy was successful in prolonging progression-free survival in certain breast cancer patients.In the trial, dubbed AVADO, doses of Avastin at both15 mg per kg of docetaxel chemotherapy and 7.5 mg per kg of chemotherapy prolonged progression-free survival, or the amount of time patients have before their tumors start growing again, in breast cancer patients who hadn't been previously treated with chemotherapy. That met the primary goal of the trial.
Genentech: Avastin Breast Cancer Study Meets Goal
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.